0001209191-21-010477.txt : 20210212
0001209191-21-010477.hdr.sgml : 20210212
20210212200015
ACCESSION NUMBER: 0001209191-21-010477
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210210
FILED AS OF DATE: 20210212
DATE AS OF CHANGE: 20210212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: RUBINSTEIN JULIE
CENTRAL INDEX KEY: 0001780664
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38957
FILM NUMBER: 21631283
MAIL ADDRESS:
STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION
STREET 2: 1551 EASTLAKE AVE E STE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp
CENTRAL INDEX KEY: 0001478320
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 270907024
STATE OF INCORPORATION: WA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: 206-659-0067
MAIL ADDRESS:
STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
FORMER COMPANY:
FORMER CONFORMED NAME: Adaptive TCR Corp
DATE OF NAME CHANGE: 20091209
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-10
0
0001478320
Adaptive Biotechnologies Corp
ADPT
0001780664
RUBINSTEIN JULIE
C/O ADAPTIVE BIOTECHNOLOGIES CORP.
SUITE 200
SEATTLE
WA
98102
0
1
0
0
President
Common Stock
2021-02-10
4
M
0
15000
6.55
A
15000
D
Common Stock
2021-02-10
4
S
0
6770
62.14
D
8230
D
Common Stock
2021-02-10
4
S
0
3814
63.00
D
4416
D
Common Stock
2021-02-10
4
S
0
3798
64.09
D
618
D
Common Stock
2021-02-10
4
S
0
618
64.76
D
0
D
Common Stock
2021-02-11
4
M
0
15000
6.55
A
15000
D
Common Stock
2021-02-11
4
S
0
10729
63.12
D
4271
D
Common Stock
2021-02-11
4
S
0
4271
63.67
D
0
D
Stock Option (Right to Buy)
6.55
2021-02-10
4
M
0
15000
0.00
D
2028-02-07
Common Stock
15000
375000
D
Stock Option (Right to Buy)
6.55
2021-02-11
4
M
0
15000
0.00
D
2028-02-07
Common Stock
15000
360000
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $61.60 to 62.58 inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $62.60 to 63.42, inclusive.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $63.60 to 64.58, inclusive.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $64.60 to 64.90, inclusive.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $62.51 to 63.50, inclusive.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $63.51 to to 63.75, inclusive.
The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
/s/ Julie Rubinstein by Eric Billings, attorney-in-fact
2021-02-12